5 unchanged sentences
Rule 10b5-1 Trading Plans
−Removed: During the three months ended June 30, 2025, no new Rule 10b5-1 trading arrangements (as defined in Item 408(a)(1)(i) of Regulation S-K) and non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act were adopted or terminated by our directors and/or executive officers (as defined in Section 16 of the Exchange Act).
−Removed: During the three months ended June 30, 2025, the Company did not adopt or terminate a Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K).
+Added: During the three months ended September 30, 2025, no new Rule 10b5-1 trading arrangements (as defined in Item 408(a)(1)(i) of Regulation S-K) and non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act were adopted or terminated by our directors and/or executive officers (as defined in Section 16 of the Exchange Act).
+Added: During the three months ended September 30, 2025, the Company did not adopt or terminate a Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K).
The exhibits listed on the Exhibit Index hereto are filed or furnished (as stated therein) as part of this Quarterly Report on Form 10‑Q.
−Removed: Amendment No.
−Removed: 3 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and CrossLink Network, LLC
−Removed: Amendment No.
−Removed: 4 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and CrossLink Network, LLC
−Removed: Management Retention Agreement, dated April 28, 2025, by and between the Company and Mark Hensley
+Added: Certificate of Designation of Rights, Preferences and Privileges of Series A Convertible Preferred Stock of Heron Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on August 11, 2025 (incorporated by reference to our Current Report on Form 8-K, as Exhibit 3.1, filed on August 12, 2025)
+Added: Certificate of Designation of Series B Preferred Stock of Heron Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on August 14, 2025 (incorporated by reference to our Current Report on Form 8-K, as Exhibit 3.1, filed on August 15, 2025
+Added: Form of Convertible Senior Unsecured Promissory Note due 2031 (included in Exhibit 10.6)
+Added: Tax Benefit Preservation Plan, dated August 14, 2025, by and between Heron Therapeutics, Inc.
+Added: and Computershare Trust Company N.A., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (incorporated by reference to our Current Report on Form 8-K, as Exhibit 4.1, filed on August 15, 2025)
+Added: Framework Agreement, dated August 6, 2025, by and between Heron Therapeutics, Inc.
+Added: and Patheon Austria GmbH & Co KG
+Added: Cooperation Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc.
+Added: and Rubric Capital Management L.P.
+Added: (incorporated by reference to our Current Report on Form 8-K, as Exhibit 10.1, filed on August 12, 2025)
+Added: Second Amendment to Working Capital Facility Agreement, dated August 8, 2025, by and between Heron Therapeutics, Inc.
+Added: and Hercules Capital, Inc., as administrative agent, collateral agent, and lender (incorporated by reference to our Current Report on Form 8-K, as Exhibit 10.2, filed on August 12, 2025)
+Added: Exchange Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc.
+Added: and the holders party thereto (incorporated by reference to our Current Report on Form 8-K, as Exhibit 10.3, filed on August 12, 2025)
+Added: Securities Purchase Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc.
+Added: and the purchasers party thereto (incorporated by reference to our Current Report on Form 8-K, as Exhibit 10.5, filed on August 12, 2025)
+Added: Note Purchase Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc.
+Added: the purchasers party from time to time thereto and Rubric Capital Management LP (incorporated by reference to our Registration Statement on Form S-3, as Exhibit 10.1, filed on September 9, 2025)
+Added: Office Lease Agreement, dated August 22, 2025, by and between Heron Therapeutics, Inc.
+Added: and USEF HCG Fenton LLC
Amendment No.
−Removed: 5 to Co-Promotion Agreement, dated as of January 5, 2024, by and between the Company and CrossLink Network, LLC
+Added: 6 to Co-Promotion Agreement, dated as of August 15, 2025, by and between the Company and Crosslink Network, LLC
Certification of Principal Executive Officer pursuant to 18 U.S.C.
18 unchanged sentences
Heron Therapeutics, Inc.
−Removed: August 8, 2025
+Added: November 4, 2025
/s/ Craig Collard
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.